Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Right now, I think one of the challenges ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Specifically for HER2-low positive breast ...

Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicinedemonstrating that calibration dramatically improves the accuracy and reproducibility of ...

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Despite recommendations for de-escalation surgical management of early-stage breast cancer in women ≥ 70 years of age, sentinel lymph node biopsy (SLNB) is still being performed for most of these ...

Unlike patients with HER2+ tumors, there is an unmet clinical need for patients with HER2-low expression cancers, which are refractory to trastuzumab. Sanofi SA has developed TPP-45142, a T-cell ...

The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The ...

HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial. This is an ...

Ninth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast09 phase 3 trial results Thirteenth Breakthrough Therapy Designation granted ...